ClinicalTrials.gg

Program

shingrix

Also written as “Herpes Zoster Vaccine GSK1437173A”, “Shingrix” and “Herpes Zoster vaccine GSK 1437173A”.

In GlaxoSmithKline's pipeline, Recombinant protein, adjuvanted vaccine. Its studies are mostly in Herpes Zoster · Cardiovascular Diseases · Respiratory Syncytial Virus Infections · Respiration Disorders, led by 2 companies.

Furthest: phase 4, since Mar 25, 202630 company-led studies, 3 open or runningNext primary completion: Aug 23, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline293 open or runningphase 4since Mar 25, 2026Feb 12, 2007Aug 23, 2027phase 3 · NCT05371080
Wuhan BravoVax10 open or runningphase 1since Jan 28, 2023Jan 28, 2023none ahead
  • Named in GlaxoSmithKline’s own pipeline as GSK1437173, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 16 studies since Feb 12, 2007.

  1. Feb 16, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02690207 · 8,687 enrolled · United States, Australia, Brazil and more
  2. Mar 10, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02723773 · 7,539 enrolled · United States, Australia, Brazil and more
  3. Apr 7, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02735915 · 70 enrolled · Czechia, Germany, Sweden
  4. Nov 29, 2016Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT02979639 · 404 enrolled · United States
  5. Feb 12, 2018Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT03439657 · 913 enrolled · United States, Canada, Estonia and more
  6. Mar 27, 2019Phase 2 study in Respiration DisordersGlaxoSmithKline · NCT03894969 · 541 enrolled · Estonia, Finland, France and more
  7. Sep 3, 2019Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT04091451 · 1,430 enrolled · Russia
  8. Nov 22, 2019Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT04176939 · 68 enrolled · Belgium, Canada, Finland and more
  9. Jan 21, 2022Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05219253 · 288 enrolled · India
  10. May 9, 2022Phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05371080 · 3,038 enrolled · United States, Australia, Brazil and more
  11. Jan 28, 2023Wuhan BravoVax's first study: phase 1 study in Herpes ZosterNew to Wuhan BravoVaxWuhan BravoVax · NCT05718037 · 40 enrolled
  12. Jul 21, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05966090 · 530 enrolled · United States, Canada
  13. Mar 25, 2026Phase 4 study in Herpes ZosterGlaxoSmithKline · NCT07502560 · 33,609 planned · Finland
  14. Oct 7, 2026Phase 3 study in Cardiovascular DiseasesGlaxoSmithKline · NCT07872046 · 16,390 planned

Ahead

  1. Aug 23, 2027Primary completion: phase 3 study in Herpes ZosterGlaxoSmithKline · NCT05371080
  2. Apr 1, 2030Primary completion: phase 4 study in Herpes ZosterGlaxoSmithKline · NCT07502560
  3. Nov 25, 2032Primary completion: phase 3 study in Cardiovascular DiseasesGlaxoSmithKline · NCT07872046

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Recombinant protein, adjuvanted vaccine”the company's pipeline, read by Claude · source
“A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both s…”NCIt, read by Claude
“Envelope glycoprotein E vaccine antigen”ChEMBL 37, by rule

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07872046Cardiovascular Diseases3Not yet recruitingGlaxoSmithKlineNov 25, 203216,390
NCT07502560Herpes Zoster · Finland4RecruitingGlaxoSmithKlineApr 1, 203033,609
NCT05966090Respiratory Syncytial Virus Infections · United States, Canada3CompletedGlaxoSmithKlineFeb 19, 2024530
NCT05718037Herpes Zoster1UNKNOWNWuhan BravoVaxJan 31, 202440
NCT05371080Herpes Zoster · United States, Australia, Brazil and more3Active, not recruitingGlaxoSmithKlineAug 23, 20273,038
NCT05219253Herpes Zoster · India3CompletedGlaxoSmithKlineOct 11, 2022288
NCT04176939Herpes Zoster · Belgium, Canada, Finland and more3CompletedGlaxoSmithKlineAug 12, 202268
NCT04091451Herpes Zoster · Russia3CompletedGlaxoSmithKlineFeb 15, 20241,430
NCT03894969Respiration Disorders · Estonia, Finland, France and more2CompletedGlaxoSmithKlineAug 31, 2020541
NCT03439657Herpes Zoster · United States, Canada, Estonia and more3CompletedGlaxoSmithKlineMay 6, 2019913
NCT02979639Herpes Zoster · United States3CompletedGlaxoSmithKlineApr 12, 2017404
NCT02735915Herpes Zoster · Czechia, Germany, Sweden3CompletedGlaxoSmithKlineAug 28, 201770
NCT02723773Herpes Zoster · United States, Australia, Brazil and more3CompletedGlaxoSmithKlineJun 28, 20237,539
NCT02690207Herpes Zoster · United States, Australia, Brazil and more3CompletedGlaxoSmithKlineMar 15, 20198,687
NCT02581410Herpes Zoster · United States3CompletedGlaxoSmithKlineAug 30, 2016430
NCT02058589Herpes Zoster · Belgium, Canada, Czechia and more3CompletedGlaxoSmithKlineMay 11, 2016265
NCT02052596Herpes Zoster · United States3CompletedGlaxoSmithKlineJun 16, 2015935
NCT02045836Herpes Zoster · United States, Canada, Estonia3CompletedGlaxoSmithKlineJul 2, 2015865
NCT01954251Herpes Zoster · United States, Canada, Germany3CompletedGlaxoSmithKlineJun 2, 2014829
NCT01798056Herpes Zoster · Canada, Czechia, France and more3CompletedGlaxoSmithKlineJun 18, 2015237
NCT01777321Herpes Zoster · Japan3CompletedGlaxoSmithKlineOct 10, 201360
NCT01751165Herpes Zoster · United States, Estonia3CompletedGlaxoSmithKlineMay 22, 2014354
NCT01610414Herpes Zoster · United States, Australia, Belgium and more3CompletedGlaxoSmithKlineNov 4, 20161,877
NCT01165229Herpes Zoster · United States, Australia, Brazil and more3CompletedGlaxoSmithKlineJul 24, 201514,819
NCT01165203Herpes Zoster · United States, Germany, United Kingdom2CompletedGlaxoSmithKlineJul 6, 2012123
NCT01165177Herpes Zoster · United States, Australia, Brazil and more3CompletedGlaxoSmithKlineMay 9, 201416,165
NCT01086449Herpes Zoster · Australia1CompletedGlaxoSmithKlineJun 25, 201020
NCT00920218Herpes Zoster · United States2CompletedGlaxoSmithKlineApr 26, 2011121
NCT00802464Herpes Zoster · United States, Czechia, Spain2CompletedGlaxoSmithKlineJul 2, 2010410
NCT00434577Herpes Zoster · Czechia, Germany, Netherlands and more2CompletedGlaxoSmithKlineOct 4, 2007715

How it is read

Names in the registry

  • “Herpes Zoster Vaccine GSK1437173A”, 6 entries
  • “Shingrix”, 3 entries
  • “Herpes Zoster vaccine GSK 1437173A”, 3 entries
  • “Herpes zoster vaccine GSK1437173A”, 3 entries
  • “HZ/su vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.